A study [71] comparing gliptins, sulphonylureas, insulin, and GLP-1 receptor agonists for use after metformin is ongoing and will possibly add knowledge about the most appropriate drugs for the treatment of T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.